OPINIONS. A Troponin Assay Conversion: What Success Looks Like WHAT MAKES TROPONIN ASSAYS DIFFERENT FROM ONE ANOTHER? ...
|
|
- Thomasine Melanie Evans
- 6 years ago
- Views:
Transcription
1 SC A Troponin Assay Conversion: What Success Looks Like Brad P. Mayeux 1 * Cardiac troponin (ctn) 2 assays have been available to the medical community for over 20 years for the aid in diagnosis, risk stratification/ prognosis, and guiding management of patients with signs and symptoms of myocardial injury and necrosis. However, we still struggle with how to synthesize the amount of information that these highly specialized assays deliver during a patient chest pain crisis. The amount of information is small a single number but the complexities are large. Transitioning assays is only one of many challenges that the majority of laboratories, and their clinician customers, face. However, successfully transitioning from one troponin assay to another is a different matter. In many instances, a laboratory makes a decision based on a number of other aspects, such as integrated platform analyzers, or middleware, and not just a ctn assay. Nonetheless, ctn can be a very polarizing assay and appears to make its way to the forefront of any instrument transition for many institutions. WHAT MAKES TROPONIN ASSAYS DIFFERENT FROM ONE ANOTHER? It is essential for stakeholders, laboratorians, and clinicians alike to understand the nuances of the different ctn assays on the market, to make decisions of which assay to use, and to have a strategy for implementation. However, if this job is done well, which includes the proper education, the average clinical practitioner will learn how to understand the performance characteristics of the ctn assays they use and how it may affect patients and their clinical practice. On the other hand, advancements in ctn assay technology have created a conundrum for clinicians and laboratorians, who must determine which assay is the best fit for optimal patient care (1). The walls that separate the laboratory from the clinical units are not only physical. Reality in the ctn world has brought to light the disparities of opinions that exist between laboratory medicine and the clinical realm. Many emergency department (ED) physicians and cardiologists, not to mention hospitalists, do not have a full understanding that many different ctn assays are available, or that concentrations obtained from the different assays do not necessarily correlate with one another. The notion of a troponin is a troponin is a troponin is quite widespread in the clinical community and difficult to dispel without proper education. Moreover, with the availability of highly sensitive ctn assays available throughout the rest of the world, and their imminent clearance by the Food and Drug Administration, more indepth knowledge and understanding will be imperative. Questions surrounding earlier and 1 Roche Diagnostics, Boston, MA. *Address correspondence to the author at: Roche Diagnostics, 9115 Hague Rd., Indianapolis, IN brad.mayeux@roche.com. DOI: /jalm American Association for Clinical Chemistry 2 Nonstandard abbreviations: ctn, cardiac troponin; ED, emergency department; MI, myocardial infarction. March : JALM 585
2 A Troponin Assay Conversion Fig. 1. Processes that have proven to be successful. Key aspects of each stage are highlighted that should be considered for clinicians and laboratorians alike during any troponin transition. more sensitive detection, possible sex-specific thresholds, cardiac injury, and types of myocardial infarction (MI) are still to be answered (2). Thought leaders throughout the US agree on one fundamental aspect; education will be critical to the success of any high-sensitivity ctn implementation. The approach that manufacturers have taken to design and develop ctn assays have many differences and are for many different reasons. The first principle is that different isoforms of ctn (ctn I and ctnt) are measured by different manufacturers' assays. Additionally, sensitivity and specificity, positive and negative predictive value, as well as accuracy and precision vary among ctn assays, creating very different tests, which physicians and other prescribing clinicians have little or no knowledge about. To overcome this knowledge gap during a ctn assay transition, implementation of a sound educational plan is essential for the laboratory to be successful in providing their clinical customers the tools they need to provide the best patient care possible. PILLARS OF SUCCESS The successful implementation of a new ctn assay occurs in several distinct stages, which can be divided into 3 main categories: pre-implementation, implementation, and post-implementation (Figure 1). Each stage has distinct attributes that contribute equally to the success of the troponin assay transition. Careful thought must be given to each stage to ensure the best outcome. In the pre-implementation stage, once selection of ctn assay has been determined, the laboratory management and staff must begin to design the education and implementation plan. Laboratory administration, pathologists, laboratory directors or managers, and chemistry supervisors alike must understand the nuances of the ctn assay selected, as well as how it 586 JALM :05 March 2017
3 A Troponin Assay Conversion OPINIONS compares to the incumbent ctn measurements. Close collaboration with the manufacturer does indeed assist with understanding the assay so that transferring knowledge to clinicians across the institution can be facilitated. A cross-specialty, multidisciplinary team should be formed to involve all necessary parties who will use and/or interpret the assay. The backbone of this ctn transition team should, at a minimum, include the laboratory, ED, cardiology, internal medicine, and hospitalist clinicians. Other members who should be assembled to form a robust transition team include nursing, risk management, and quality assurance. One of the most crucial tasks for this team is to determine decision thresholds that the clinical staff will use for given patient populations. Discussion of non-st-elevation MI guidelines (3), as they relate to the universally recommended use of the 99th percentile of a reference control population for the ctn assay, should be conducted when determining appropriate decision thresholds. This, in many instances, requires explanation to the clinical staff as to what the 99th percentile actually is regarding ctn troponin testing. The use of a sensitive contemporary ctn assay at a decision threshold of the 99th percentile will improve diagnostic performance, and these assays can potentially have a substantial impact in improving early diagnosis and outcomes of acute MI patients (4). This should most certainly involve a clinical discussion between cardiology and the ED clinicians, as sensitivity and specificity are used differently within these 2 clinical areas. Successful ctn transitions include one, if not several, meetings among the laboratory and these 2 clinical areas to determine the most suitable decision thresholds for the patient population for which the institution provides care. Evidence-based laboratory guidance and input are essential during this process, since clinicians rely heavily on this knowledge, sometimes without question, and clinician groups do not always understand the analytical variables that influence laboratory results and potential issues that may arise during implementation (5). Therefore, laboratory medicine expertise and guidance helps to reduce the confusion and increase the understanding of the new troponin assay and its performance. Cardiac troponin assay correlation studies are not typical and should be designed and carried out carefully. Comparison of the current and new ctn assay should be executed carefully, eliminating any potential variables. For example, analyzing one ctn sample batch after a freeze-thaw cycle and not the other, or using the 99th percentile for one assay and not the other, may greatly affect the outcome of the study. Analytical comparison of ctn assays may be very complex. However, a clinical correlation is the most prudent method to compare the incumbent ctn and the new assays, to show how they compare clinically. Review of these data should be discussed in an open forum, and a qualified labortorian should be involved before implementation occurs. The implementation phase of any ctn may provoke anxiety for any laboratory, whether large or small. However, the thoughtfully laid plans mentioned earlier will help to ensure success during this stage of the transition. Preparation begins with more involvement and interaction among the multidisciplinary team. It is imperative to have laboratory representation at ED, cardiology, and hospitalist/internal medicine departmental meetings to help educate all physicians, nurse practitioners, physician assistants, and any other prescriber who interprets ctn results in their clinical decision-making. Most specialty groups within medical institutions have regular staff meetings, and this is frequently the best venue for reaching as many clinicians as possible. An intended short 10- to 15-minute time slot at the beginning of a departmental meeting agenda will frequently expand to minutes when discussing the value of the assay and clinical implications, including the potential March : JALM 587
4 A Troponin Assay Conversion impact on patient outcomes. This discourse will prove to be invaluable to the entire transition process. Another effective tool that should be used is to disseminate an informative implementation or transition letter, which is a simple way to distribute the vital assay information to all clinical staff. Recommended contents should include sections that speak to decision thresholds, analytical performance, reference to published literature, and other pertinent evidence deemed necessary by the multidisciplinary team. Opinions may differ on timing, but many believe that an initial announcement approximately 1 or 2 weeks before transition, with a follow-up letter the day before transition, would be highly advisable. FLIPPING THE SWITCH In all likelihood, ctn will not be the only assay that will be transitioning during an implementation. Additionally, one very important consideration is to continue serial measurements of the incumbent ctn assay on patients who presented to the ED during the transition. Keeping the current ctn available and online for hours to finish any patient serial measurements should be heavily weighted, since ctn assays do not correlate numerically and could have an adverse impact on the decisions clinicians will make. All newly presenting patients after the transition will then be followed serially with the newly implemented ctn assay. Laboratory vigilance during the first days of the transition is essential to help guide clinicians who were not able to benefit fully from the education before the transition, as well as answer any questions that may arise. The post-implementation stage is the final important part of any ctn transition process. During this period, an ongoing process of verifying the accuracy of assay performance should be continued, as is done for most clinical assays. To keep track of the effect of the transition on clinical care, key outcomes such as laboratory turnaround time and the prevalence of elevated ctn results in hospital admissions for suspected acute coronary syndrome should be monitored. Follow-up with clinicians at the aforementioned periodic departmental meetings is imperative to ensuring the success of any ctn transition. Reeducating on proper use of ctn assay will more than likely be necessary and will strengthen the probability of a successful transition. CONCLUSION Transition to a new ctn assay can be a daunting task for any laboratory and institution to undertake. However, with careful selection of the ctn assay appropriate for the patient population served, proper planning, and comprehensive collaboration and education of the clinical staff, the transition can occur without disruption of the medical value that the laboratory brings to their clinicians and the patients to whom they provide care. Moreover, this collaboration will likely have the effect of strengthening the relationship between the laboratory and the clinicians to whom they provide a valuable service and form a true partnership between 2 important entities within the institution. 588 JALM :05 March 2017
5 A Troponin Assay Conversion OPINIONS Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 4 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; (c) final approval of the published article; and (d) agreement to be accountable for all aspects of the article thus ensuring that questions related to the accuracy or integrity of any part of the article are appropriately investigated and resolved. Authors Disclosures or Potential Conflicts of Interest: No authors declared any potential conflicts of interest. Role of Sponsor: No sponsor was declared. REFERENCES 1. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem 2009;55: Korley FK, Jaffe AS. High-sensitivity troponin: where are we now and where do we go from here? Biomark Med 2014;8: Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al AHA/ACC guidelines for management of patients with non-stelevation acute coronary syndromes. J Am Coll Cardiol 2014;64: Korley FK, Jaffe AS. High sensitive cardiac troponin assays: how to implement them successfully. ejifcc 2016;27: Reichlin T, Hochholzer W, Bassetti S, Steuer S, Stelzig C, Hartwiger S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med 2009;361: March : JALM 589
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory
More informationPerformance requirements for ctni measurement in clinical setting: need to standardize as well
5 th International CIRME Meeting STANDARDIZATION OF CARDIAC TROPONIN I: THE ONGOING IINTERNATIONAL EFFORTS NOVEMBER 30 th, 2011 Centre for Metrological Traceability in Laboratory Medicine (CIRME) Director:
More informationHow Logistics Enables the Healthcare Revolution. Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company
How Logistics Enables the Healthcare Revolution Richard Holmes Managing Director of Polar Speed Distribution Ltd, a UPS company Introduction There is a revolution taking place in healthcare delivery. Patient-centred
More informationComparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study
ARTICLES SC Comparison of 13 Commercially Available Cardiac Troponin Assays in a Multicenter North American Study Robert H. Christenson, 1 * Ellis Jacobs, 2,3 Denise Uettwiller-Geiger, 4 Mathew P. Estey,
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationThe Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview
The Endocrine Society Strategic Plan 2011 (Approved by Council on June 2, 2011) Strategic Plan Overview Mission: The mission of The Endocrine Society is to advance excellence in endocrinology and promote
More informationOn the Revision of the Standards and Practice Standards for. Management Assessment and Audit concerning Internal Control
(Provisional translation) On the Revision of the Standards and Practice Standards for Management Assessment and Audit concerning Internal Control Over Financial Reporting (Council Opinions) Released on
More information9/7/17. Implementing the ARK Immunoassay for Therapeutic Drug Monitoring of High-Dose Methotrexate. Disclosure. Learning Objectives
Implementing the ARK Immunoassay for Therapeutic Drug Monitoring of High-Dose Methotrexate Kristine R. Crews, PharmD, FCCP, BCPS St. Jude Children s Research Hospital September 14, 2017 Disclosure I declare
More informationINFORMATION GOVERNANCE STRATEGY. Documentation control
INFORMATION GOVERNANCE STRATEGY Documentation control Reference Date Approved Approving Body Version Supersedes Consultation Undertaken Target Audience Supporting procedures GG/INF/01 TRUST BOARD Information
More informationSTATEMENT SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION AND RESEARCH U.S. FOOD AND DRUG ADMINISTRATION BEFORE THE
DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Food and Drug Administration Rockville MD 20857 STATEMENT OF SANDRA KWEDER, M.D DEPUTY DIRECTOR, OFFICE OF NEW DRUGS CENTER FOR DRUG EVALUATION
More informationContinuing Professional Development (CPD) Requirements for New Zealand Licensed Auditors
Policy and guidance Continuing Professional Development (CPD) Requirements for New Zealand Licensed Auditors (Effective 1 July 2016) CONTENTS 1 CPD Policy for New Zealand licensed auditors... 3 1.1 Introduction...
More informationGovernance Policies for PCORnet, the National Patient-Centered Clinical Research Network
Governance Policies for PCORnet, the National Patient-Centered Clinical Research Network 1.0 Leadership and Decision-Making When reading this document it is important to note that there are several categories
More informationICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions. Step 3
European Medicines Agency June 2009 EMEA/CHMP/ICH/380636/2009 ICH Topic E16 Genomic Biomarkers Related to Drug Response: Context, Structure and Format of Qualification Submissions Step 3 NOTE FOR GUIDANCE
More informationGuidance Note: Corporate Governance - Audit Committee. March Ce document est aussi disponible en français.
Guidance Note: Corporate Governance - Audit Committee March 2015 Ce document est aussi disponible en français. Applicability The Guidance Note: Corporate Governance Audit Committee (the Guidance Note )
More informationThe Top Healthcare Compensation Issues for 2016
TRENDS & ISSUES The Top Healthcare Compensation Issues for 2016 AUTHORS Steve Sullivan Principal Transformation in healthcare is an extended journey over uncharted waters, featuring untested business strategies,
More informationThe future of PMS in Healthcare IT: Announcing the cooperation with Epic. Stan Smits CEO Medical IT Philips Medical Systems
The future of PMS in Healthcare IT: Announcing the cooperation with Epic Stan Smits CEO Medical IT Philips Agenda Healthcare IT: business rationale Why Epic? Scope of the cooperation agreement Company
More informationFINAL DOCUMENT. Global Harmonization Task Force. Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts
GHTF/SG5/N6:2012 FINAL DOCUMENT Global Harmonization Task Force Title: Clinical Evidence for IVD medical devices Key Definitions and Concepts Authoring Group: Study Group 5 of the Global Harmonization
More informationA Guide to Clinical Coding Audit Best Practice Version 8.0
A Guide to Clinical Coding Audit Best Practice Version 8.0 Copyright 2017 Health and Social Care Information Centre Page 1 of 17 The Health and Social Care Information Centre is a non-departmental body
More informationFrom EAP to BHAP. A Guide for Fire Departments. Firefighters and their families must have access to. Firefighter Life Safety Initiative #13:
From EAP to BHAP A Guide for Fire Departments Introduction: Firefighter Life Safety Initiative #13: Firefighters and their families must have access to counseling and psychological support. Firefighters
More informationRegulatory Overview of Proposed LDT Framework. FDA Concerns. Background. FDA Proposed Regulatory Approach. By Ben Berg, Meaghan Bailey, RAC
Regulatory Overview of Proposed LDT Framework By Ben Berg, Meaghan Bailey, RAC On July 31, 2014, the U.S. Food and Drug Administration (FDA or the Agency) notified both the Senate Committee on Health,
More informationPhUSE Paper RG06. Quality Risk Radar for the Outsourcing of Clinical Trials The Best Guide to Success
Paper RG06 Quality Risk Radar for the Outsourcing of Clinical Trials The Best Guide to Success Randy Ramin-Wright and Raffael Jovine International Institute for the Safety of Medicines (ii4sm) Basel, Switzerland
More informationMyeloma UK Policy Working with the Pharmaceutical Industry
Policy Working with the Pharmaceutical Industry Background The relationship between patient organisations and the pharmaceutical industry has come under increasing scrutiny in recent times, with the media
More informationA Guide for Assessing Health Research Knowledge Translation (KT) Plans
A Guide for Assessing Health Research Knowledge Translation (KT) Plans Developed as part of a research study being conducted by investigators from the Centre for Addiction and Mental Health and McMaster
More informationGood morning ladies and gentlemen, Thank you for inviting me to talk about the IVD industry.
Good morning ladies and gentlemen, Thank you for inviting me to talk about the IVD industry. We are entering a new era of much needed regulatory oversight which might seem a daunting task at first. I am
More informationIBL LTD AUDIT AND RISK COMMITTEE TERMS OF REFERENCE
IBL LTD AUDIT AND RISK COMMITTEE TERMS OF REFERENCE 1. Overall Purpose/Objectives 1.1 The Audit and Risk Committee, while assisting the Board in fulfilling its oversight responsibilities, will also be
More informationRegional Genomics Service Improvement Lead Job Description and Person Specification
Regional Genomics Service Improvement Lead Job Description and Person Specification Position Job title Regional Genomics Service Improvement Lead Directorate Medical Directorate Pay band AFC Band 8d Responsible
More informationBayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans
Bayer Corporate Policy: Global Publications Deriving from Clinical Studies in Humans Overview The key aspects of this Global Publication Policy are commitment to publish; consistent application of authorship
More informationQuality Assurance of Investigational Medicinal Products. Sue McKenzie PPQA (A)
Quality Assurance of Investigational Medicinal Products Sue McKenzie PPQA (A) Agenda for Today IMP Regulations - CTD and Annex 13 Role of QP for IMP Challenges of IMP Manufacture for the QP IMP Regulations
More informationQ-STRESS CARDIAC STRESS TESTING SYSTEM
Q-STRESS CARDIAC STRESS TESTING SYSTEM This product is available through: JRT Associates 800-221-0111 A Legacy of Clinical Excellence Mortara brings proven expertise to the forefront of diagnostic cardiac
More informationJune 2013 Clinical Laboratory News: Volume 39, Number 6
June 2013 Clinical Laboratory News: Volume 39, Number 6 Competency Assessment Does the New CLIA Guidance Mean Big Changes? By Bill Malone Laboratory professionals work in one of the most highly regulated
More informationAuditing Standard for Islamic Financial Institutions No. 6
Auditing Standard for Islamic Financial Institutions No. 6 External Shari ah Audit (Independent Assurance Engagement on an Islamic Financial Institution s Compliance with Shari ah Principles and Rules)
More informationMEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155
MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155 EXECUTIVE SUMMARY Medical device regulations around the world generally require manufacturers of most types of medical devices to supply data as part
More informationUNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS
UNANNOUNCED EU MEDICAL DEVICE AUDITS BY NOTIFIED BODIES: IMPACT ON SUPPLIERS Executive Summary European Medicines Agency (EMA) regulations for licensing of medical devices include the use of authorized
More informationForecast diagnostics for antimicrobial resistance (AMR)
Forecast diagnostics for antimicrobial resistance (AMR) Authors: Ann Van den Bruel, Philip Turner NIHR Diagnostic Evidence Cooperative Oxford, University of Oxford Context When asked to make forecasts
More informationOff-Label Use of FDA-Approved Drugs and Biologicals
Off-Label Use of FDA-Approved Drugs and Biologicals Last Review Date: January 12, 2018 Number: MG.MM.AD.06cC2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More informationFDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies
ADVISORY February 2011 FDA s Final Rule on Medical Device Data Systems Signals Active Regulation of Data Communication Technologies Contacts On February 15, 2011, the U.S. Food and Drug Administration
More informationEstablishment of Clinical Trial Infrastructure
Taiwan s Strategy in the Establishment of Clinical Trial Infrastructure Chei-Hsiang Chen, Ph. D. Director, Biotechnology and Pharmaceutical Industries Program Office, Ministry of Economic Affairs, Taiwan
More informationProgress in Healthcare IT
Progress in Healthcare IT Stan Smits Medical IT Philips Agenda The Healthcare IT market IT embedded in PMS products Philips is a leader in PACS Alliance with Epic for Enterprise Software 2 Challenges in
More informationRole of the WHO IVD Prequalification Programme in Light of National Regulatory Authority Approval
Role of the WHO IVD Prequalification Programme in Light of National Regulatory Authority Approval UN Prequalification of Medicines, Diagnostics and Vaccines 6 th Consultative Stakeholder Meeting 4 April
More informationChallenges of Analytical Method Transfer in the Pharmaceutical Industry
Challenges of Analytical Method Transfer in the Pharmaceutical Industry White Paper Author: Steve Alley, Technical Specialist 1 Contents Introduction 2 Method Transfer Team 3 Identify Methods 4 Gap Analysis
More informationSummary of Medicines Plan
Summary of Medicines Plan Ministry of Public Health, Welfare and Sport Summary of Medicines Plan 1 Content Introduction 4 1 Accessibility of innovative medicines 5 Go to action 2 Tackle the high price
More informationMedical Device Development Tools. Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff
Reprinted from FDA s website by Medical Device Development Tools Draft Guidance for Industry, Tool Developers, and Food and Drug Administration Staff DRAFT GUIDANCE This guidance document is being distributed
More informationChapter 7E: Nurturing Human Capital/Focus on Staff
Chapter 7E: Nurturing Human Capital/Focus on Staff Starting Points The following points made by Jim Collins (author of the bestseller Good to Great; Why Some Companies Make the Leap And others Don t) are
More informationHealthcare Compensation Surveys
2018 Healthcare Compensation Surveys THE DATA YOU NEED FOR THE DECISIONS YOU MAKE 2018 Enhancements now available for MORE PARTICIPANTS Data-Extraction Template pg. 17 focus on Industry Segments with surveys
More informationDMC membership experience. P.Bauer Basel May 2016
DMC membership experience P.Bauer Basel May 2016 EMA GUIDELINE ON DATA MONITORING COMMITTEES Clinical trials frequently extend over a long period of time. Thus, for ethical reasons it is desirable to ensure
More informationDECLARATION OF ANDREW SAXON, M.D. knowledge, and if called to testify, I could competently do so.
0 WILSHIRE BOULEVARD, TH FLOOR LOS ANGELES, CALIFORNIA 00-0 TELEPHONE --00 FAX --0 DECLARATION OF ANDREW SAXON, M.D. I, Andrew Saxon, M.D., declare as follows:. I am over years of age. I know the following
More informationFlorida State University Policy 7-IRB-
Florida State University Policy 7-IRB- Title of Policy: Institutional Review Board Jurisdiction/Applicability Responsible Executive: Gary K. Ostrander Approving Official: Gary K. Ostrander Effective Date:
More informationNHSLA Risk Management Standards for NHS Trusts Providing Community Services 2011/12
NHSLA Risk Management Standards for NHS Trusts Providing Community Services 2011/12 Milton Keynes Primary Care Trust Provider of Community and Mental Health Services Level 1 May 2011 Contents Page 1: Executive
More informationSUBJECT: INSTITUTIONAL REVIEW BOARD (IRB) - HUMANITARIAN USE DEVICES
This policy applies to the following entity(s): Children s Hospital of Wisconsin Children s Hospital and Health System, Inc. Administrative Policy and Procedure Children s Research Institute SUBJECT: INSTITUTIONAL
More informationThe Promise of Data-Driven Healthcare
The Promise of Data-Driven Healthcare MegaTrends for 2018 and Beyond February 27, 2018 Presenters 1 Valerie Barton, Managing Director Valerie oversees Manatt s data and analytics capability. She works
More informationBIOTECH, MED DEVICE & PHARMA
WHITEPAPER Key Account Management Strategies for BIOTECH, MED DEVICE & PHARMA INTRODUCTION Changes in the healthcare landscape have led to changes in customers. In an environment where healthcare providers
More informationKathy O Kane Kreutzer, M.Ed., Office of Faculty Affairs, School of Medicine March, 2017
SOM Authorship Guidelines, Recent Updates to the ICMJE Uniform Requirements for Scholarship, and the Emerging Role of Social Media in Monitoring Scholarship Kathy O Kane Kreutzer, M.Ed., Office of Faculty
More informationCherryRoad Technologies Inc. Property of
Aligning Strategic Project Goals with Organizational Goals During Technology Implementations: Hospitals & Health Systems www.cherryroad.com Recently, a senior executive of a Midwestern Hospital & Health
More informationNoncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant.
Noncommercial culture and drug-susceptibility testing methods for screening patients at risk for multidrugresistant tuberculosis Policy statement March 2010 1 Contents Abbreviations Executive summary 1.
More informationHow to Become a Member of MINT
How to Become a Member of MINT MINT and its members receive regular requests about how one can become a member of MINT. This document describes current policies and practices related to this question.
More informationMEDICAL COUNCIL OF NEW ZEALAND
MEDICAL COUNCIL OF NEW ZEALAND NOVEMBER 16 www.mcnz.org.nz Statement on advertising Introduction 1. The Medical Council believes that clear and accurate information about the services provided by doctors
More informationThe following are matters specifically reserved for the Board:-
To establish and review training programme and succession planning to the Board and all candidates appointed to senior management positions are of sufficient calibre; To approve the change of corporate
More informationValidating electronic source data in clinical trials
Controlled Clinical Trials 25 (2004) 437 446 www.elsevier.com/locate/conclintrial Validating electronic source data in clinical trials Ronald G. Marks* Department of Biostatistics, College of Medicine,
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationMcKesson Cardiology Bringing together all the cardiovascular information you need into a single platform
Care Providers Hospitals and Health Systems Enterprise Image and Information Management McKesson Cardiology Bringing together all the cardiovascular information you need into a single platform Catheterization
More informationMYELOMA EURONET COMMENTS ON THE EC PUBLIC CONSULTATION RARE DISEASES: EUROPE S CHALLENGES
MYELOMA EURONET COMMENTS ON THE EC PUBLIC CONSULTATION RARE DISEASES: EUROPE S CHALLENGES Myeloma Euronet, the European Network of Myeloma Patient Groups (www.myeloma-euronet.org), is an international
More informationObjectives. April 9, Property of Oscar Gallardo, PT, DPT, NCS. Do not copy without permission. Cultural Competence:
Cultural Competence: Oscar Gallardo, PT, DPT, NCS April 9, 2016 Objectives 1. Understand why cultural competence is important for providing quality care 2. Define Cultural Competence 3. Learn strategies
More informationIT S TIME! PRIMARIS OPERATIONAL EFFICIENCY SOLUTION. Using Lean Thinking to Save Time & Money. Benefits of Operational Efficiency. Why Primaris?
IT S TIME! PRIMARIS OPERATIONAL EFFICIENCY SOLUTION Using Lean Thinking to Save Time & Money Healthcare executives are well aware that both government agencies and private insurers are moving away from
More informationAllergan plc COMPREHENSIVE COMPLIANCE PROGRAM
Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM 1. Compliance with Law All colleagues, officers and directors of the Company shall respect and comply with all applicable federal, state, local and foreign
More informationOperational Plan
Operational Plan 05-06 0 Contents Contents... Glossary... Strategic Plan... Focus Area One: Our clinicians, patients, health care partners and the community... 5 Connecting people with ideas to make a
More informationMid-America Intergovernmental Audit Forum. Selecting an External Auditor. Guide for Making a Sound Decision
Mid-America Intergovernmental Audit Forum Selecting an External Auditor Guide for Making a Sound Decision May 2007 Foreword The benefits of having a high-quality audit of a government's financial statements
More informationRISK AND AUDIT COMMITTEE TERMS OF REFERENCE
RISK AND AUDIT COMMITTEE TERMS OF REFERENCE Brief description Defines the Terms of Reference for the Risk and Audit Committee. BHP Billiton Limited & BHP Billiton Plc BHP Billiton Limited & BHP Billiton
More informationEthical leadership and corporate citizenship. Applied. Applied. Applied. Company s ethics are managed effectively.
CORPORATE GOVERNANCE- KING III COMPLIANCE Analysis of the application as at 24 June 2015 by Master Drilling Group Limited (the Company) of the 75 corporate governance principles as recommended by the King
More informationPersonalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies
Personalised Healthcare Solutions (PHCS) Excellence for your Biomarker-driven Strategies The value of In Vitro Diagnostics The value of diagnostics as an integral part in the healthcare value chain Diagnostics
More informationCORPORATE GOVERNANCE KING III COMPLIANCE REGISTER 2017
CORPORATE GOVERNANCE KING III COMPLIANCE REGISTER 2017 This document has been prepared in terms of the JSE Listing Requirements and sets out the application of the 75 corporate governance principles by
More informationCCQM P58.1: Metrology for Clinical Sciences. Diagnostic Formulation Meeting, 24 th Feb James Noble
CCQM P58.1: Metrology for Clinical Sciences Diagnostic Formulation Meeting, 24 th Feb James Noble Development of a Reference Immunoassay for ctni Cardiac Troponin I (ctni) is an important marker for the
More informationADES International Holding Ltd (the Company )
ADES International Holding Ltd (the Company ) Terms of Reference of the Audit Committee (The Committee ) (approved at a meeting of the board of directors (the Board ) held on 9 May 2017) 1. Introduction
More informationProject Brief. Royal Columbian Hospital Redevelopment Project Phase One
Royal Columbian Hospital Redevelopment Project Phase One Page i TABLE OF CONTENTS 1 INTRODUCTION... 1 1.1 Purpose of this... 1 2 THE BUSINESS OPPORTUNITY... 2 3 FRASER HEALTH AUTHORITY... 4 4 THE PROJECT...
More informationAction Plan 14/14 Managing Long Term Sickness NICE PH19 June 2014
Action Plan 14/14 Managing Long Term Sickness NICE PH19 June 2014 Title: Action Plan 14/14 Managing Long Term Sickness NICE PH 19 (Published 03/2009) Prepared by: Presented by: Main aim: Recommendations:
More informationIntroduction to Clinical Research
Introduction to Clinical Research What is Clinical Research? Clinical research is medical research that involves people like you. People volunteer to participate in carefully conducted investigations that
More informationHEDIS Measures NCQA s 20 Years of Experience with Measurement
HEDIS Measures NCQA s 20 Years of Experience with Measurement For twenty years, NCQA has refined our process for developing, testing, implementing and maintaining health care quality measures. Researchers,
More informationHealth Workforce New Zealand
Health Workforce New Zealand About HWNZ Health Workforce New Zealand (HWNZ) was established in October 2009, following a government review of health services and reports from government-established commissions
More informationSample Pages Alliance Management Guidebook
313 Washington Street, Suite 300 Newton, MA 02458 USA PHONE +1 617.965.4777 FAX +1 617.965.8558 www.rhythmofbusiness.com Sample Pages Management Guidebook Managing Biopharma Strategic s Collaborative Networks
More informationDue diligence in the European medical devices industry
Due diligence in the European medical devices industry Alison Dennis, Reed Smith LLP www.practicallaw.com/0-205-5707 As the medical devices industry is highly regulated, determining a target company's
More informationOHM MODULES. Appointment Scheduler. Billing Manager. For more information call or visit ULehssustainability.com/ohm
OHM MODULES Occupational Health Manager (OHM) is a multi-module software solution that gives you all the detailed tracking and reporting tools you need to streamline information management, maximize consistency
More informationMAC 800 Resting ECG System. Connecting hearts and minds.
GE Healthcare MAC 800 Resting ECG System Connecting hearts and minds. MAC 800 connectivity XML SD PC or EMR Workstation XML LAN/Shared Directory CardioSoft (CS) or MUSE Modem Cardiology Management Systems
More informationGuidance on Data Monitoring Committee: Regulatory Perspective in Japan
Austria-Japan Joint Statistics Workshop Data monitoring committees in clinical trials Guidance on Data Monitoring Committee: Regulatory Perspective in Japan Yuki Ando Senior Scientist for Biostatics Pharmaceuticals
More informationelevating the role of finance at Mary Lanning Healthcare
CASE STUDY REPRINT November 2013 Amanda Hoffman Jay Spence healthcare financial management association hfma.org elevating the role of finance at Mary Lanning Healthcare One central Nebraska hospital sought
More informationSTRATEGIC FRAMEWORK. National CASA Association
STRATEGIC FRAMEWORK National CASA Association Summary This document contains the detailed strategic framework presented on and discussed at the National CASA Association Board meeting occurring on May
More informationCRO partner in Rx/CDx Co-Development
CRO partner in Rx/CDx Co-Development DEDICATED DIALOGUE A sponsored roundtable discussion published in Pharmaceutical Executive Two Covance executives discuss a CRO s role in supporting Companion Diagnostics
More informationAUDIT COMMITTEE CHARTER
AUDIT COMMITTEE CHARTER Role and Responsibilities The Board of The Institute of Internal Auditors Australia (IIA-Australia) has established a Board Audit Committee as part of its responsibilities in relation
More informationApril 13, Background
Pfizer Inc 235 East 42nd Street New York, NY 10017-5755 Tel 212 733 4210 Fax 646 383 9249 Email: marc.wilenzick@pfizer.com April 13, 2009 http://www.regulations.gov Christine Ireland Committee management
More informationThe New England Journal of Medicine. Special Articles CONFLICT-OF-INTEREST POLICIES FOR INVESTIGATORS IN CLINICAL TRIALS
Special Articles CONFLICT-OF-INTEREST POLICIES FOR INVESTIGATORS IN CLINICAL TRIALS BERNARD LO, M.D., LESLIE E. WOLF, J.D., M.P.H., AND ABIONA BERKELEY, J.D. ABSTRACT Background There is substantial concern
More informationWorld Medical Association Declaration of Helsinki
World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly Helsinki, Finland, June 1964 and amended by the
More informationImpact of New Proposals on Name Creation for 87 th PTMG Conference Vienna, Austria
Impact of New Proposals on Name Creation for 87 th PTMG Conference Vienna, Austria Susan M. Proulx, PharmD President, Med-ERRS www.med-errs.com A subsidiary of the Institute for Safe Medication Practices
More informationJoint Evaluation of Joint Programmes on Gender Equality in the United Nations System Management Response
drafted by: Working Group (UN Women, UNDP, UNFPA, UNICEF, MDGF/UNDP) Date: 5/16/2014 Overall : The interagency group which commissioned the Joint Evaluation of Joint Programmes on Gender Equality in the
More informationActing Deputy Commissioner for Operations, U.S. Food and Drug Administration
Available on FDA website at: http://www.fda.gov/newsevents/testimony/ucm113266.htm Pediatric Clinical Trials for Anti-depressant Drug Products Statement of Janet Woodcock, M.D. Acting Deputy Commissioner
More informationValue Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool
Value Messages: Developing, Incorporating, and Making Use of a Core Strategic Tool Kati Copley-Merriman, MBA, MS Vice President, Regulatory and Health Outcomes Strategy RTI Health Solutions Stephanie Barrows,
More informationSmouldering myeloma. Myeloma Infosheet Series. Other related conditions. Infoline:
Smouldering myeloma This Infosheet provides information on what smouldering myeloma is, how it is diagnosed, what the treatment is and will explain the link between smouldering myeloma and active myeloma.
More information(Adopted by the Board of Directors on 13 May 2009 and amended on 24 September 2009, 13 September 2012 and 27 November 2013)
Thomas Cook Group plc THE AUDIT COMMITTEE TERMS OF REFERENCE (Adopted by the Board of Directors on 13 May 2009 and amended on 24 September 2009, 13 September 2012 and 27 November 2013) Chairman and members
More informationCIMA GATEWAY CASE STUDY MARCH 2015 EXAM ANSWERS. Variant 3
CIMA GATEWAY CASE STUDY MARCH 2015 EXAM ANSWERS Variant 3 https://connect.cimaglobal.com/resources/gateway-exam/february-2015-gateway-case-studyexam---bild-variant-number-3 The March 2015 Exam can be viewed
More informationGender Parity Strategy
Gender Parity Strategy 25 January 2018 Table of Contents Introduction... 2 1 UNOPS is Committed to Gender Parity... 3 1.1 The Case for Gender Parity and Inclusiveness... 3 2 UNOPS CONTEXT... 4 2.1 Gender
More informationToo Much of a Good Thing?
Regulatory s Role in Reviewing External Corporate Communications Too Much of a Good Thing? By John Driscoll Every regulatory professional is a reviewer. One could even say that the majority of our work
More information